Kemwell BiopharmaKemwell Biopharma is a leading biologics CDMO based in Bengaluru, India, offering end-to-end services from cell line and process development to cGMP clinical and commercial manufacturing. Its 15,000 sq. m facility, built with Boehringer Ingelheim, includes 5,000 L bioreactor capacity and sterile fill-finish for vials and PFS. In October 2025, Kemwell completed a U.S. FDA PAI for an injectable drug product, reinforcing its global quality standards and trusted partnerships since 1980.Kemwell specializes in mammalian cell-based biologics, including mAbs, complex proteins and biosimilars.
